Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9682763 | 0.79 | NAPRT (0.42) | SMN1; SMN2LMNAL3MBTL1ADRB2ADRB1 | |
| SCHEMBL9226765 | 0.78 | FDPS (0.45) | SMN1; SMN2LMNAL3MBTL1NAPRTCFTR | |
| SCHEMBL2488308 | 0.77 | LMNA (0.50) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL7875002 | 0.77 | LMNA (0.50) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL3087768 | 0.77 | ADRB3 (0.47) | SMN1; SMN2LMNAL3MBTL1ADRB2ADRB1 | |
| SCHEMBL5147826 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAL3MBTL1NAPRTCFTR | |
| SCHEMBL25233552 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAL3MBTL1ADRB1CFTR | |
| SCHEMBL4476838 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAL3MBTL1CFTRSLC6A2 | |
| SCHEMBL6075149 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAL3MBTL1CFTRSLC6A2 | |
| SCHEMBL6927013 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAL3MBTL1ADRB1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| CN-101208325-A | Heteroarylvinyl derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1904471-A1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2007006459-A1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| EP-0603557-B1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM CO (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5461126-A | Process of polymerizing olefins using organonickel catalyst compositions | PHILLIPS PETROLEUM COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5332708-A | Ethylene polymerization catalyst, organonickel compound and a heterocyclic nitrogen compound | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0603557-A1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP1A1, CYP3A5 | SMN1; SMN2 4219/4885LMNA 2115/4885L3MBTL1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.